CN1744889A - 坦洛新的控释药物组合物 - Google Patents

坦洛新的控释药物组合物 Download PDF

Info

Publication number
CN1744889A
CN1744889A CNA2003801094133A CN200380109413A CN1744889A CN 1744889 A CN1744889 A CN 1744889A CN A2003801094133 A CNA2003801094133 A CN A2003801094133A CN 200380109413 A CN200380109413 A CN 200380109413A CN 1744889 A CN1744889 A CN 1744889A
Authority
CN
China
Prior art keywords
compositions
tamsulosin
mixture
cellulose
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801094133A
Other languages
English (en)
Chinese (zh)
Inventor
G·K·简恩
S·西塔拉恩
A·兰帕尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of CN1744889A publication Critical patent/CN1744889A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2003801094133A 2002-12-20 2003-12-18 坦洛新的控释药物组合物 Pending CN1744889A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1292DE2002 IN192381B (cg-RX-API-DMAC7.html) 2002-12-20 2002-12-20
IN1292/DEL/2002 2002-12-20

Publications (1)

Publication Number Publication Date
CN1744889A true CN1744889A (zh) 2006-03-08

Family

ID=32676755

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2003801094133A Pending CN1744889A (zh) 2002-12-20 2003-12-18 坦洛新的控释药物组合物

Country Status (9)

Country Link
EP (1) EP1596849A1 (cg-RX-API-DMAC7.html)
JP (1) JP2006512358A (cg-RX-API-DMAC7.html)
CN (1) CN1744889A (cg-RX-API-DMAC7.html)
AU (1) AU2003288604A1 (cg-RX-API-DMAC7.html)
BR (1) BR0317567A (cg-RX-API-DMAC7.html)
CA (1) CA2511208A1 (cg-RX-API-DMAC7.html)
IN (1) IN192381B (cg-RX-API-DMAC7.html)
RU (1) RU2005121999A (cg-RX-API-DMAC7.html)
WO (1) WO2004056354A1 (cg-RX-API-DMAC7.html)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008089593A1 (fr) * 2007-01-18 2008-07-31 Standard Chem. & Pharm. Co., Ltd. Preparation de tamsulosine a liberation prolongee et procede de production associe
CN101695478B (zh) * 2009-10-23 2012-01-18 江苏大学 盐酸坦索罗辛缓释微丸制剂及其制备方法
CN102970985A (zh) * 2010-05-04 2013-03-13 株式会社三养生物制药 包含坦洛新或其药学可接受的盐的控释药物组合物及包含所述药物组合物的口服制剂
CN103142492A (zh) * 2013-02-01 2013-06-12 北京科信必成医药科技发展有限公司 一种缓释微丸制剂及其制备方法
CN103315962A (zh) * 2013-02-01 2013-09-25 北京科信必成医药科技发展有限公司 一种坦索罗辛缓释微丸制剂及其制备方法
CN103919735A (zh) * 2014-05-04 2014-07-16 翰宇药业（武汉）有限公司 一种盐酸坦索罗辛缓释微丸及其制备方法
CN101453996B (zh) * 2006-04-03 2016-05-11 伊萨·奥迪迪 药物递送组合物
WO2025201521A1 (zh) * 2024-03-29 2025-10-02 南京三迭纪医药科技有限公司 一种调节释放的口服药物剂型及其制备方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2515585A1 (en) * 2003-01-27 2004-08-12 Yoji Tanijiri Enteric sustained-release fine particles for tamsulosin or its salt and manufacturing method thereof
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
PL1618873T3 (pl) * 2004-07-14 2008-01-31 Siegfried Generics Int Ag Granulat do kontrolowanego uwalniania tamsulozyny, zawierający alginian
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US8529953B2 (en) * 2008-07-01 2013-09-10 Sawai Pharmaceutical Co., Ltd. Process for production of spherical microparticles comprising tamsulosin hydrochloride
ES2555485T1 (es) 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
KR20190019061A (ko) * 2016-05-04 2019-02-26 아스펜 파크 파마슈티컬스 인코포레이티드 지연된 방출 경구 탐술로신 하이드로클로라이드
EP3473245A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
EP3473244A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
KR20200078146A (ko) * 2018-12-21 2020-07-01 한미약품 주식회사 내산성이 우수한 탐수로신 염산염 함유 제약 조성물 및 이의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
ATE321544T1 (de) * 2001-11-07 2006-04-15 Synthon Bv Tamsulosin tabletten

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101453996B (zh) * 2006-04-03 2016-05-11 伊萨·奥迪迪 药物递送组合物
WO2008089593A1 (fr) * 2007-01-18 2008-07-31 Standard Chem. & Pharm. Co., Ltd. Preparation de tamsulosine a liberation prolongee et procede de production associe
CN101695478B (zh) * 2009-10-23 2012-01-18 江苏大学 盐酸坦索罗辛缓释微丸制剂及其制备方法
CN102970985A (zh) * 2010-05-04 2013-03-13 株式会社三养生物制药 包含坦洛新或其药学可接受的盐的控释药物组合物及包含所述药物组合物的口服制剂
CN103142492A (zh) * 2013-02-01 2013-06-12 北京科信必成医药科技发展有限公司 一种缓释微丸制剂及其制备方法
CN103315962A (zh) * 2013-02-01 2013-09-25 北京科信必成医药科技发展有限公司 一种坦索罗辛缓释微丸制剂及其制备方法
CN103919735A (zh) * 2014-05-04 2014-07-16 翰宇药业（武汉）有限公司 一种盐酸坦索罗辛缓释微丸及其制备方法
WO2025201521A1 (zh) * 2024-03-29 2025-10-02 南京三迭纪医药科技有限公司 一种调节释放的口服药物剂型及其制备方法

Also Published As

Publication number Publication date
BR0317567A (pt) 2005-11-22
EP1596849A1 (en) 2005-11-23
IN192381B (cg-RX-API-DMAC7.html) 2004-04-10
RU2005121999A (ru) 2006-01-20
CA2511208A1 (en) 2004-07-08
JP2006512358A (ja) 2006-04-13
WO2004056354A1 (en) 2004-07-08
AU2003288604A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
CN1744889A (zh) 坦洛新的控释药物组合物
CN1023293C (zh) 一种含有美多心安盐的控制释放制剂的制备方法
EP1976489B1 (en) Multiple unit type sustained release oral formulation comprising zaltoprofen and process for the preparation thereof
KR101752014B1 (ko) 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
CN1178650C (zh) 搅动非依赖性多元缓释药物制剂及其制备方法
JP4971159B2 (ja) プラミペキソール又はその薬学的に許容しうる塩を含有する徐放性ペレット製剤、その製法及び使用
CN1170540C (zh) 茶碱缓释片
CN1198591C (zh) 在口服固体剂型中包含依普沙坦的生物利用度提高的制剂
CN1886120A (zh) 用于制备可口腔给药的固态药物组合物的方法
CN1384740A (zh) 含有曲马朵糖精盐的持续释放给药剂型
CN1384739A (zh) 缓释的口服药物形式
CN1474687A (zh) 基于抗高血糖药微胶囊的延时释放药物
HK1209337A1 (en) Medicament-containing hollow particle
CN1148171C (zh) 多单元缓释片剂
JP2019527700A (ja) タムスロシン塩酸塩含有徐放性ペレットを含む、溶出率が制御された経口投与用薬剤学的製剤
CN1178659C (zh) 控释活性化合物的药物制剂
CN1046459A (zh) 剂量形式的美贝维林
CN1842331A (zh) 含有氨磺必利的新颖固体药物组合物
CN1893927A (zh) 抗生素组合物
CN1681493A (zh) 掩味舒马曲坦片剂及其制备方法
CN1758903A (zh) 坦洛新或其盐的肠缓释微粒及其制造方法
JP2012503665A (ja) アリスキレンを含むガレヌス製剤および溶融押出し造粒によるその調製方法
TWI745598B (zh) 非布司他控釋組合物及其製備方法
KR100510270B1 (ko) 펠렛타이저를 이용한 서방성 제제의 제조방법
JP2018508501A (ja) タムスロシン塩酸塩含有徐放性顆粒を含む経口用薬剤学的製剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication